Long-Term Follow-Up of Ultrasound-Guided Glossopharyngeal Nerve Block Treatment for Glossopharyngeal Neuralgia: A Retrospective Clinical Study of 43 Cases
Shaohua You,Xiaoyan Qin,Li Tong,Zeguo Feng
DOI: https://doi.org/10.2147/jpr.s437609
IF: 2.8319
2024-03-07
Journal of Pain Research
Abstract:Shaohua You, 1, &ast Xiaoyan Qin, 2, &ast Li Tong, 3 Zeguo Feng 1 1 Department of Pain Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People's Republic of China; 2 Department of Clinical Laboratory, Shijingshan Teaching Hospital of Capital Medical University, Beijing Shijingshan Hospital, Beijing, 100049, People's Republic of China; 3 Department of Anesthesiology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People's Republic of China &astThese authors contributed equally to this work Correspondence: Zeguo Feng, Department of Pain Medicine, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People's Republic of China, Email ; Li Tong, Department of Anesthesiology, The First Medical Center of Chinese PLA General Hospital, Beijing, 100853, People's Republic of China, Email Background: Glossopharyngeal neuralgia (GPN) is a rare chronic neuropathic pain disorder that significantly impacts quality of life. Ultrasound-guided glossopharyngeal nerve blocks (UGPNB) have gained popularity due to their various advantages. However, there have been no studies reporting the long-term outcomes of UGPNB in a larger cohort of GPN patients. Aim: This study aims to evaluate the efficacy and safety of UGPNB in patients with GPN. Methods: We reviewed the electronic medical records of patients with GPN who received UGPNB at the Department of Pain Medicine of the First Medical Center, PLA General Hospital between June 1, 2011, and June 1, 2022. The effect of UGPNB was evaluated using the Barrow Neurological Institute (BNI) scale. Improvement was defined as a reduction in pain category by comparing pain categories before and after therapy. Recovery was defined as achieving BNI I after treatment. Patients who responded to treatment but then regressed to the category before therapy were considered to have experienced pain relapse. Results: A total of 43 patients with GPN who received UGPNB were included in the analysis. At discharge, 35 (81.4%) patients experienced pain improvement after treatment, and among them, 13 (30.2%) patients achieved recovery. After discharge, 13 patients (37.1%) out of the 35 effective patients experienced pain relapse at different time intervals: 0.5, 0.7, 1, 1, 3, 3, 4, 12, 15, 36, 45, 63, and 96 months. The cumulative recurrence-free survival rates were 88.85% at month 1, 82.83% at month 3, 77.04% at month 12, 70.31% at month 36, and 54.66% at month 120. Among the 13 patients who experienced relapse, four patients received a second UGPNB treatment, and pain improved in two patients (50%). No severe adverse reactions were documented. Conclusion: UGPNB is an effective, repeatable, safe, and minimally invasive treatment for patients with GPN. It may be preferable to consider UGPNB before undergoing invasive intracranial surgery or neurodestructive methods. Keywords: ultrasound-guided glossopharyngeal nerve block, glossopharyngeal neuralgia, efficacy, safety Glossopharyngeal neuralgia (GPN) is a painful condition associated with the cranial nerve (CN) IX that is characterized by unilateral, brief, and stabbing pains. These pains are typically localized in the ear, base of the tongue, tonsillar fossa, and/or beneath the angle of the jaw. They can be triggered by swallowing, talking, coughing, chewing, or yawning but may also occur spontaneously with abrupt onset and termination. 1,2 Despite being a rare cause of craniofacial pain, representing only 0.2% to 1.3% of facial pain syndromes, GPN has an estimated overall incidence of 0.2 cases per 100,000 people each year 3,4 significantly impacting both the quality of life and socioeconomic functioning of patients. 5 The International Classification of Headache Disorders, 3rd edition, categorizes GPN into classical, secondary, and idiopathic types, 1 with classical GPN often being attributed to neurovascular compression, secondary GPN resulting from an underlying disease, and idiopathic GPN having an unknown etiology. In rare cases, GPN can present in conjunction with vagal symptoms such as cough, hoarseness, syncope, and/or bradycardia—a condition some authors have termed vagoglossopharyngeal neuralgia. 6,7 Current first-line medical treatments for GPN include carbamazepine or oxcarbazepine, with their side effects being the primary reason for treatment discontinuation. 8,9 In scenarios where oral medications are not suitable, microvascular decompression (MVD) is regarded as a viable treatment choice for classical GPN, 5,10,11 although it comes with potential complications such as hearin -Abstract Truncated-
clinical neurology